DeVere White RW - Search Results

1

Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy.

Ho PY, Duan Z, Batra N, Jilek JL, Tu MJ, Qiu JX, Hu Z, Wun T, Lara PN, DeVere White RW, Chen HW, Yu AM. Ho PY, et al. Among authors: devere white rw. J Pharmacol Exp Ther. 2018 Jun;365(3):494-506. doi: 10.1124/jpet.118.247775. Epub 2018 Mar 30. J Pharmacol Exp Ther. 2018. PMID: 29602831 Free PMC article.

2

Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.

Liu HL, Gandour-Edwards R, Lara PN Jr, de Vere White R, LaSalle JM. Liu HL, et al. Cancer J. 2001 Sep-Oct;7(5):395-403. Cancer J. 2001. PMID: 11693898

3

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R. Gandour-Edwards R, et al. Cancer. 2002 Sep 1;95(5):1009-15. doi: 10.1002/cncr.10808. Cancer. 2002. PMID: 12209684 Free article.

4

ACTR/AIB1/SRC-3 and androgen receptor control prostate cancer cell proliferation and tumor growth through direct control of cell cycle genes.

Zou JX, Zhong Z, Shi XB, Tepper CG, deVere White RW, Kung HJ, Chen H. Zou JX, et al. Among authors: devere white rw. Prostate. 2006 Oct 1;66(14):1474-86. doi: 10.1002/pros.20477. Prostate. 2006. PMID: 16921507

5

Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells.

Ma AH, Xia L, Desai SJ, Boucher DL, Guan Y, Shih HM, Shi XB, deVere White RW, Chen HW, Tepper CG, Kung HJ. Ma AH, et al. Among authors: devere white rw. Cancer Res. 2006 Sep 1;66(17):8439-47. doi: 10.1158/0008-5472.CAN-06-1636. Cancer Res. 2006. PMID: 16951154

6

Accrual issues in genitourinary cancer clinical trials.

Lara PN Jr, de Vere White R. Lara PN Jr, et al. Urol Oncol. 2006 Sep-Oct;24(5):379-83. doi: 10.1016/j.urolonc.2005.11.037. Urol Oncol. 2006. PMID: 16962485 No abstract available.

7

Inhibition of Akt pathways in the treatment of prostate cancer.

Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN Jr. Nelson EC, et al. Among authors: devere white rw. Prostate Cancer Prostatic Dis. 2007;10(4):331-9. doi: 10.1038/sj.pcan.4500974. Epub 2007 May 1. Prostate Cancer Prostatic Dis. 2007. PMID: 17471291 Review.

8

Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.

Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN Jr, de Vere White RW. Vinall RL, et al. Clin Cancer Res. 2007 Oct 15;13(20):6204-16. doi: 10.1158/1078-0432.CCR-07-0600. Clin Cancer Res. 2007. PMID: 17947488

9

Current applications for prostate-specific antigen doubling time.

Ramírez ML, Nelson EC, Devere White RW, Lara PN Jr, Evans CP. Ramírez ML, et al. Among authors: devere white rw. Eur Urol. 2008 Aug;54(2):291-300. doi: 10.1016/j.eururo.2008.04.003. Epub 2008 Apr 11. Eur Urol. 2008. PMID: 18439749 Review.

10

Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.

Shi XB, Xue L, Zou JX, Gandour-Edwards R, Chen H, deVere White RW. Shi XB, et al. Among authors: devere white rw. Prostate. 2008 Dec 1;68(16):1816-26. doi: 10.1002/pros.20849. Prostate. 2008. PMID: 18780293

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page